NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021

Autor:	Aaron C. Shaver, Mark W. Clemens, Mary A. Dwyer, Youn H. Kim, Joan Guitart, Lubomir Sokol, Jeffrey A. Barnes, Jasmine Zain, Basem M. William, Neha Mehta-Shah, Ahmad Halwani, Allison Jones, Carlos A. Torres-Cabala, Ahmet Dogan, Bradley M. Haverkos, Pallawi Torka, Stephen M. Ansell, Eric D. Jacobsen, Gaurav Goyal, Hema Sundar, Ryan A. Wilcox, Sima Rozati, Deepa Jagadeesh, Barbara Pro, Saurabh Rajguru, Aaron M. Goodman, Richard T. Hoppe, Jonathan W. Said, Andrei R. Shustov, Stefan K. Barta, Weiyun Z. Ai, Steven M. Horwitz, Elise A. Olsen
Rok vydání:	2020
Předmět:	Oncology medicine.medical_specialty business.industry T cell Clinical course Disease Immune dysregulation medicine.disease medicine.disease_cause Lymphoma medicine.anatomical_structure Immune system Internal medicine medicine Conventional chemotherapy Bone marrow business
Zdroj:	Journal of the National Comprehensive Cancer Network. 18:1460-1467
ISSN:	1540-1413 1540-1405
DOI:	10.6004/jnccn.2020.0053
Popis:	Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of T-cell lymphoma associated with an aggressive clinical course and a worse prognosis. HSTCL develops in the setting of chronic immune suppression or immune dysregulation in up to 20% of cases and is most often characterized by spleen, liver, and bone marrow involvement. Diagnosis and management of HSTCL pose significant challenges given the rarity of the disease along with the absence of lymphadenopathy and poor outcome with conventional chemotherapy regimens. These Guidelines Insights focus on the diagnosis and treatment of HSTCL as outlined in the NCCN Guidelines for T-Cell Lymphomas.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::5e1a93979b15addd9bfc550452532c3e https://doi.org/10.6004/jnccn.2020.0053 Zobrazit plný text záznamu